济南挺而不硬怎么办(济南阴囊长了个包) (今日更新中)

BEIJING, March 22 (Xinhua) -- China's State Food and Drug Administration (SFDA) has ordered a "serious investigation" into two kinds of bath products that reportedly gave children skin diseases.The order came after recent reports accused the body wash and lotion used by bathhouse chain Tian Po Po Xi Jiu Tang, or, literally, "Grandma Tian's Bathhouse," in southwest China's Sichuan Province of having "caused severe body damages," according to a SFDA statement released Tuesday.The bathhouse chain, with a history of some 70 years, was first established in Sichuan's capital Chengdu and was listed as a part of the city's Intangible Cultural Heritage in 2009.The licensed bathhouse claimed to use bath products developed by its own Chinese herbal medicine recipes that protected children from various skin ailments and other diseases, such as eczema, colds, and constipation.However, an unknown number of children suffered pustular psoriasis, a chronic skin irritation characterize by raised bumps, after washing at the bathhouse chain and using the two products, according to reports.Sichuan's provincial food and drug administration bureau previously deemed the two products to be "fake drugs" based on an initial investigation by the local police and food and drug authorities, the statement said.The SFDA urged local food and drug supervision departments across the country to monitor and check the two products sold by the bathhouse chain within their regions, and vowed to punish any violations of laws and regulations.

LOS ANGELES, May 29 (Xinhua) -- Nineteen percent of

BEIJING, Feb. 9 (Xinhua) -- The Chinese currency, or the yuan, rose to a new high of 6.585 against the U.S. dollar Wednesday, according to the China Foreign Exchange Trading System.The central parity rate of the RMB, or the yuan, was 10 basis points higher than the previous record of 6.586 set on Feb. 1, the previous trading day.The yuan appreciated 3.6 percent last year, but some analysts predict it could rise further against the dollar this year as the People's Bank of China (PBOC), the central bank, attempts to cool accelerating inflation.The PBOC announced Tuesday it would raise the benchmark one-year borrowing and lending rates by 25 basis points from Wednesday.On China's foreign exchange spot market, the yuan can rise or fall 0.5 percent from the central parity rate each trading day.The central parity rate of the RMB against the U.S. dollar is based on a weighted average of prices before the opening of the market each business day.

MOSCOW, Jan. 24 (Xinhua) -- China and Russia held the fifth round of strategic security talks here Monday, pledging more joint efforts to strengthen national, regional and international security.The Chinese delegation, led by Chinese State Councilor Dai Bingguo, was visiting Russia at the invitation of Russian Security Council Secretary Nikolai Patrushev.During the talks, the two parties exchanged views on major international issues and the further development of strategic partnership and interaction between Russia and China.Both sides agreed that their close bilateral cooperation on global issues has helped maintain regional and world peace, safety and stability.The two countries acknowledged that in order to further enhance strategic mutual trust and improve the security situation around the global, the two sides should chart the development of Sino- Russian relations for the next 10 years from a strategic and comprehensive perspective.As long-time strategic partners, Russia and China will adhere to the principles of mutual trust, win-win cooperation and good neighborliness while conducting strategic coordination, the two sides pledged.The fourth round of Sino-Russian security consultations took place in Beijing in December 2009, when Russia and China signed a protocol on cooperation in the strategic security sphere. The next round of talks is scheduled to be held later this year in China.

WASHINGTON, March 24 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Thursday approved the use of Zostavax, a live attenuated virus vaccine, for the prevention of shingles in individuals 50 to 59 years of age. Zostavax is already approved for use in individuals 60 years of age and older.In the United States shingles affects approximately 200,000 healthy people between the ages of 50 and 59, per year. It is a disease caused by the varicella-zoster virus, which is a virus in the herpes family and the same virus that causes chickenpox.After an attack of chickenpox, the virus lies dormant in certain nerves in the body. For reasons that are not fully understood, the virus can reappear in the form of shingles, more commonly in people with weakened immune systems and with aging."The likelihood of shingles increases with age. The availability of Zostavax to a younger age group provides an additional opportunity to prevent this often painful and debilitating disease" said Karen Midthun, director of FDA's Center for Biologics Evaluation and Research, in a statement. ( Shingles is characterized by a rash of blisters, which generally develop in a band on one side of the body and can cause severe pain that may last for weeks, and in some people, for months or years after the episode.Approval was based on a multicenter study conducted in the United States and four other countries in approximately 22,000 people who were 50-59 years of age. Half received Zostavax and half received a placebo. Study participants were then monitored for at least one year to see if they developed shingles. Compared with placebo, Zostavax reduced the risk of developing shingles by approximately 70 percent.The most common side effects observed in the study were redness, pain and swelling at the site of injection, and headache, according to the FDA.Zostavax, manufactured by Merck & Co., was originally approved on May 26, 2006, for the prevention of shingles in individuals 60 years of age and older.

来源：资阳报